Apogee Therapeutics announced that it has commenced an underwritten public offering of approximately $350M of shares of its common stock. All of the securities are being offered by Apogee. Jefferies, BofA Securities, Goldman Sachs, TD Cowen, and Stifel are acting as joint book-running managers for the proposed offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APGE:
- Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
- Apogee Therapeutics Unveils Promising APG777 Phase 1 Data
- Apogee Therapeutics Announces Breakthrough Phase 1 Results
- Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
